The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
2d
MarketBeat on MSNGilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on the cloud-based software company's stock, anticipating AI-driven gains.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results